Estimating asymptomatic SARS-CoV-2 infections in a geographic area of low disease incidence.


Journal

BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551

Informations de publication

Date de publication:
15 Apr 2021
Historique:
received: 29 01 2021
accepted: 05 04 2021
entrez: 15 4 2021
pubmed: 16 4 2021
medline: 22 4 2021
Statut: epublish

Résumé

The SARS-CoV-2 infection has emerged as a rapidly spreading infection. Today it is relatively easy to isolate Covid-19 symptomatic cases, while remains problematic to control the disease spread by infected but symptom-free individuals. The control of this possible path of contagion requires drastic measures of social distancing, which imply the suspension of most activities and generate economic and social issues. This study is aimed at estimating the percentage of asymptomatic SARS-CoV-2 infection in a geographic area with relatively low incidence of Covid-19. Blood serum samples from 388 healthy volunteers were analyzed for the presence of anti-SARS-CoV-2 IgG by using an ELISA assay based on recombinant viral nucleocapsid protein. We found that 7 out of 388 healthy volunteers, who declared no symptoms of Covid-19, like fever, cough, fatigue etc., in the preceding 5 months, have bona fide serum anti-SARS-CoV-2 IgG, that is 1.8% of the asymptomatic population (95% confidence interval: 0.69-2.91%). The estimated range of asymptomatic individuals with anti-SARS-CoV-2 IgG should be between 26,565 and 112, 350. In the same geographic area, there are 4665 symptomatic diagnosed cases.

Sections du résumé

BACKGROUND BACKGROUND
The SARS-CoV-2 infection has emerged as a rapidly spreading infection. Today it is relatively easy to isolate Covid-19 symptomatic cases, while remains problematic to control the disease spread by infected but symptom-free individuals. The control of this possible path of contagion requires drastic measures of social distancing, which imply the suspension of most activities and generate economic and social issues. This study is aimed at estimating the percentage of asymptomatic SARS-CoV-2 infection in a geographic area with relatively low incidence of Covid-19.
METHODS METHODS
Blood serum samples from 388 healthy volunteers were analyzed for the presence of anti-SARS-CoV-2 IgG by using an ELISA assay based on recombinant viral nucleocapsid protein.
RESULTS RESULTS
We found that 7 out of 388 healthy volunteers, who declared no symptoms of Covid-19, like fever, cough, fatigue etc., in the preceding 5 months, have bona fide serum anti-SARS-CoV-2 IgG, that is 1.8% of the asymptomatic population (95% confidence interval: 0.69-2.91%).
CONCLUSIONS CONCLUSIONS
The estimated range of asymptomatic individuals with anti-SARS-CoV-2 IgG should be between 26,565 and 112, 350. In the same geographic area, there are 4665 symptomatic diagnosed cases.

Identifiants

pubmed: 33853532
doi: 10.1186/s12879-021-06054-2
pii: 10.1186/s12879-021-06054-2
pmc: PMC8046491
doi:

Substances chimiques

Antibodies, Viral 0
Immunoglobulin G 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

350

Références

J Infect Dev Ctries. 2020 May 31;14(5):440-446
pubmed: 32525828
J Med Virol. 2021 Mar;93(3):1739-1742
pubmed: 32790086
Internist (Berl). 2020 Aug;61(8):782-788
pubmed: 32548652
Future Sci OA. 2021 Jan 12;7(4):FSO673
pubmed: 33815819
Lancet Infect Dis. 2020 Jul;20(7):758-759
pubmed: 32330441
Appl Health Econ Health Policy. 2020 Aug;18(4):509-517
pubmed: 32495067
Nature. 2020 Jan;577(7792):605-607
pubmed: 31992880
Pathogens. 2021 Feb 03;10(2):
pubmed: 33546341
J Clin Med. 2020 Feb 04;9(2):
pubmed: 32033064
J Med Virol. 2021 Feb;93(2):803-811
pubmed: 32667733
Front Public Health. 2020 Jun 10;8:262
pubmed: 32587844
Euro Surveill. 2020 Mar;25(10):
pubmed: 32183930

Auteurs

Valeria Caturano (V)

Department of Molecular Medicine and Medical Biotechnology, University of Napoli Federico II, Via S. Pansini 5, 80131, Naples, Italy.

Barbara Manti (B)

Department of Molecular Medicine and Medical Biotechnology, University of Napoli Federico II, Via S. Pansini 5, 80131, Naples, Italy.

Fortunata Carbone (F)

Istituto di Endocrinologia e Oncologia Sperimentale, Consiglio Nazionale Delle Ricerche (IEOS-CNR), Naples, Italy.

Vito Alessandro Lasorsa (VA)

Department of Molecular Medicine and Medical Biotechnology, University of Napoli Federico II, Via S. Pansini 5, 80131, Naples, Italy.
CEINGE Biotecnologie Avanzate s.c.ar.l., Naples, Italy.

Roberta Colicchio (R)

Department of Molecular Medicine and Medical Biotechnology, University of Napoli Federico II, Via S. Pansini 5, 80131, Naples, Italy.

Mario Capasso (M)

Department of Molecular Medicine and Medical Biotechnology, University of Napoli Federico II, Via S. Pansini 5, 80131, Naples, Italy.
CEINGE Biotecnologie Avanzate s.c.ar.l., Naples, Italy.

Antonio Leonardi (A)

Department of Molecular Medicine and Medical Biotechnology, University of Napoli Federico II, Via S. Pansini 5, 80131, Naples, Italy.

Giuseppe Matarese (G)

Department of Molecular Medicine and Medical Biotechnology, University of Napoli Federico II, Via S. Pansini 5, 80131, Naples, Italy.
Istituto di Endocrinologia e Oncologia Sperimentale, Consiglio Nazionale Delle Ricerche (IEOS-CNR), Naples, Italy.

Tommaso Russo (T)

Department of Molecular Medicine and Medical Biotechnology, University of Napoli Federico II, Via S. Pansini 5, 80131, Naples, Italy. tommaso.russo@unina.it.

Paola Salvatore (P)

Department of Molecular Medicine and Medical Biotechnology, University of Napoli Federico II, Via S. Pansini 5, 80131, Naples, Italy. paola.salvatore@unina.it.
CEINGE Biotecnologie Avanzate s.c.ar.l., Naples, Italy. paola.salvatore@unina.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH